Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: A case report

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

124 Downloads (Pure)

Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury. Nowadays, aHUS is successfully treated with eculizumab, a humanized, chimeric IgG2/4 kappa antibody, which binds human complement C5 and blocks generation of C5a and membrane-attack-complex. Case presentation: A 25-year-old woman with end stage renal disease due to relapsing atypical hemolytic uremic syndrome had a relapse of the disease during pregnancy. She was treated with eculizumab. We measured reduced formation of the membrane-attack complex in newborn's umbilical cord vein blood using the sensitive and specific Palarasah-Nielsen-ELISA. Conclusions: Eculizumab treatment of the mother with end stage renal disease may cause reduced innate immunity which could render newborns more susceptible to infections.

OriginalsprogEngelsk
Artikelnummer307
TidsskriftBMC Nephrology
Vol/bind20
Udgave nummer1
Sider (fra-til)307
Antal sider5
ISSN1471-2369
DOI
StatusUdgivet - 7. aug. 2019

Fingeraftryk

Dyk ned i forskningsemnerne om 'Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: A case report'. Sammen danner de et unikt fingeraftryk.

Citationsformater